725 related articles for article (PubMed ID: 31601406)
1. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
3. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
4. Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC; Fogaça MV; Sonego AB; Guimarães FS
Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
[TBL] [Abstract][Full Text] [Related]
6. Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
Newton M; Newton DW
J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
[No Abstract] [Full Text] [Related]
8. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.
Ożarowski M; Karpiński TM; Zielińska A; Souto EB; Wielgus K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919010
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Pina SD; Tambaro S; Memo M; Mastinu A
Life Sci; 2019 May; 224():120-127. PubMed ID: 30910646
[TBL] [Abstract][Full Text] [Related]
10. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
[TBL] [Abstract][Full Text] [Related]
14. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Zlebnik NE; Cheer JF
Annu Rev Neurosci; 2016 Jul; 39():1-17. PubMed ID: 27023732
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for cannabidiol in psychiatry?
Khoury JM; Neves MCLD; Roque MAV; Queiroz DAB; Corrêa de Freitas AA; de Fátima Â; Moreira FA; Garcia FD
World J Biol Psychiatry; 2019 Feb; 20(2):101-116. PubMed ID: 28112021
[TBL] [Abstract][Full Text] [Related]
16. Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.
Ortiz R; Rueda S; Di Ciano P
Exp Clin Psychopharmacol; 2023 Oct; 31(5):978-988. PubMed ID: 37126037
[TBL] [Abstract][Full Text] [Related]
17. A scoping review of the use of cannabidiol in psychiatric disorders.
Kirkland AE; Fadus MC; Gruber SA; Gray KM; Wilens TE; Squeglia LM
Psychiatry Res; 2022 Feb; 308():114347. PubMed ID: 34952255
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Zuardi AW
Braz J Psychiatry; 2008 Sep; 30(3):271-80. PubMed ID: 18833429
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
García-Gutiérrez MS; Navarrete F; Gasparyan A; Austrich-Olivares A; Sala F; Manzanares J
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228239
[TBL] [Abstract][Full Text] [Related]
20. The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets.
Vitale RM; Iannotti FA; Amodeo P
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]